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ABSTRACT
Isotretinoin, most often recognized by the brand name Accutane, is regarded by
many patients and prescribers as the miracle cure for acne. Its unsurpassed efficacy is
paired with serious risk of adverse events and birth defects, which poses ethical questions
regarding its safety and necessity. Its regulatory history established precedent in Food
and Drug Administration Risk Evaluation and Mitigation Strategies and brought
awareness to the sharp dangers of teratogenic drug use.
This medication came as a breakthrough solution to patients that suffered years of
unsuccessful regimens for the treatment of acne vulgaris. Some question the risk-benefit
evaluation of such a toxic drug for acne. It was noted in Archives of Family Medicine
that “although acne is not a life-threatening disease, it has significant physical and
psychological ramifications such as permanent scarring, poor self-image, social
inhibition, depression and anxiety” (Thiboutot). Significant health implications press the
need for such an effective drug. Accutane and isotretinoin generic drugs have changed
the lives of over two million patients (AOCD).
Despite the remarkable success, the significant dangers must not be overlooked.
Measures have been put in place such as a Black Box warning, categorization as
Category X pregnancy risk, and the REMS program “iPLEDGE”, but significant adverse
events and pregnancy issues continue to be reported. Regulatory history and extreme
legal backlash quickly caused the brand-name Accutane by Hoffmann-La Roche to be
taken off the market, but numerous isotretinoin generic formulations continue to be
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profitable and prescribed to patients daily. Although many still confuse isotretinoin drugs
and refer to all of these medications as “Accutane”, this drug is no longer distributed or
prescribed. When a patient says they are taking “Accutane”, they are most likely
receiving an isotretinoin drug almost identical to Accutane, but produced by a different
company. The household name recognition that Accutane achieved after litigation
remains in dermatological vocabulary although it has been discontinued.
The REMS of isotretinoin aims to (1) to prevent fetal exposure and (2) to inform
prescribers, pharmacists, and patients about isotretinoin’s serious risks and safe-use
conditions (FDA). The stringent regulations of this drug and its implications on the
pharmacological safety environment warrants scrutinous evaluation and review. How has
the FDA, the pharmaceutical industry, and the healthcare industry, in general, responded
to high risk drugs (like Accutane) with significant adverse events in recent years?
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INTRODUCTION TO ISOTRETINOIN (ACCUTANE®)
Introduction
Isotretinoin, the oral acne medication more commonly known by the former brand
name Accutane, has been a miracle acne medication for numerous patients, but not
without significant side effects. Its unmatched efficacy comes with serious questions
regarding its safety. This medication approved for marketing in 1982 fights “severe
recalcitrant nodular acne” (Roche Laboratories Inc.). This critical statement is repeated
numerous times throughout the Accutane package insert and holds a very particular
meaning upon examination. This particular form of acne culminates in the presence of
numerous, inflamed nodes that are usually larger than 5 millimeters. In the package insert
it notes that this medication “should be reserved for patients with severe nodular acne
who are unresponsive to conventional therapy, including systemic antibiotics” (Roche
Laboratories Inc.). In other words, this medication is withheld only for patients -who
have already completed altogether unsuccessful or perhaps minimally successful months
to years of topical acne treatments, antibiotic courses, or other dermatological treatments.
This drug should by no means serve as a first-line acne medication. Once the patient has
proven to be unresponsive to these other treatments, their doctor may talk to them about
starting isotretinoin oral capsules.
The side effects of this medicine are far-reaching and can include dermatological
implications, psychiatric diagnoses, gastrointestinal complications, skeletal issues, and
other adverse events troubling other systems of the body. Incontestably, the drug’s
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intense efficacy affects body systems other than the integumentary system alone. The
extremely high risk for severe birth defects is a huge aspect within precautions of the
drug and warrants a Black Box warning from the United States Food and Drug
Administration (FDA).
Due to the significant side effects and Black Box warning, Accutane and its
equivalents were eventually required to be dispensed only under a special restricted
distribution program called iPLEDGE. The prescriber, patient, and pharmacist must meet
the monthly required interactions of the program to be able to access the drug. This is a
form of a Risk Evaluation and Mitigations Strategy (REMS) plan as specified by the
FDA. The goals as stated on the Food and Drug Administration’s website states that the
goals of the isotretinoin risk evaluation and mitigation strategy are to prevent fetal
exposure to isotretinoin and to inform prescribers, pharmacists, and patients about
isotretinoin’s serious risks and safe-use conditions (FDA).
Data Acquisition
As an in-depth review, this thesis required numerous sources from primary and
secondary literature. The package inserts of the isotretinoin drugs are thorough and
provided ample information about the pharmacologic properties of the drug along with
lengthy descriptions of potential adverse events. The FDA REMS website provided upto-date information regarding specific isotretinoin REMS goals. The iPledge website and
materials served to explain the program and its goals. There are numerous published
explanations of sections of Hoffmann-La Roche history, and I used many of these sources
to create a timeline of the regulatory history. I read through numerous efficacy studies
and published clinical trials regarding safe-use conditions. I also explored the
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pharmacology of birth defects more as my topic developed, as this proved to be an
interesting area of pharmacy that I am excited to learn more about.
As a personal anecdote, I was able to travel to Boston with the Honors College
Junior Quest program to interview professionals with potential insight on my topic. I met
with Dr. Kesselheim, who sparked my interests in the specific area of study into the
iPledge program more particularly with regards to birth defects. This was when I began
to switch my study focus from more of the lawsuit and litigation history to the specific
goals and pharmacological implications of isotretinoin REMS. With all of my collected
sources and personal experience, I produced my thorough case-study and in-depth review
of Accutane.
What is Isotretinoin (Accutane)?
Isotretinoin is a retinoid drug that works to fight acne by inhibiting sebaceous
gland function and keratinization (Leyden, et al.). Acne vulgaris is a “chronic
inflammatory disease of pilosebaceous follicles commonly affecting adolescents and
young adults” (On, et.al.). The disease pathogenesis of acne is “multifactorial, caused by
a combination of follicular hyperkeratinization, sebum production, Propionibacterium
acnes (P. acnes) colonization, and inflammation” (On, et al.). Acne affects patients of all
ages and ethnicities. While isotretinoin is supposedly withheld for patients displaying
severe recalcitrant nodular acne, this definition provides blurry standards. It is ultimately
up to the discretion of the dermatologist and patient to determine the next step of their
journey to clear skin. It has been brought to attention that in current practice, off-label
uses include only moderate acne, as well as high-risk neuroblastoma, rosacea, and
psoriasis (Leyden, et al). Isotretinoin treats acne caused by “androgen stimulation of
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sebaceous glands leads [which] leads to an increase in sebum, which provides a favorable
environment for P. acnes' growth” (On, et al.). What makes isotretinoin unique is that it
treats not only one, but all of the top four most common causes of acne in the same oral
dosage form.
Figure 1 shows the chemical structure of isotretinoin. Chemically, it is a 13-cisretinoic acid. This active ingredient is related to retinoic acid and retinol (Vitamin A).

Figure 1. Chemical Structure of Isotretinoin

The ingredient description is described below.
Active Ingredient: Isotretinoin
Inactive Ingredients: beeswax, butylated hydroxyanisole, edetate disodium,
hydrogenated soybean oil flakes, hydrogenated vegetable oil, and soybean oil.
Chemical formula: C H O
20

28
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IUPAC name: (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona2,4,6,8-tetraenoic acid (Lexicomp)

Pharmacology
The isotretinoin package insert states that “the exact mechanism of action of
isotretinoin is unknown'' (FDA). Isotretinoin is relatively water-soluble and metabolized
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by the cytochrome P450 liver enzyme into active metabolite 4‐oxo‐isotretinoin.
Isotretinoin acts as a “pro‐drug… converted into five major active metabolites (13‐cis‐4‐
oxo‐retinoic acid/4‐oxo‐isotretinoin, all‐trans‐retinoic acid/tretinoin, all‐trans‐4‐oxo‐
retinoic acid/4‐oxo‐tretinoin, 9‐cis‐retinoic acid, and 9‐cis‐4‐oxo‐retinoic acid)” (Layton).
These isomerize and bind to the alpha and gamma retinoic acid receptors (RARs) to
“exert its anti‐proliferative effect on sebocytes, consequently inhibiting cell
differentiation, sebum secretion, and sebaceous gland size” (On, et al.). The maximum
plasma concentration of isotretinoin is reached within 4-6 hours, and the peak of 4‐oxo‐
isotretinoin is reached in 6-20 hours (Khoo). The duration and intensity of the dosage for
this medication varies based on the individual patient case.
The decrease in sebum secretion is temporary and related to the decrease in
sebaceous gland size. The differentiation of various sebaceous gland cells is inhibited
during the isotretinoin therapy as well (Layton).
The package insert for Accutane recommends 0.5 to 1.0 mg/kg/day given in two
divided doses with food for 15 to 20 weeks or until cumulative drug levels have been
reached (Roche Laboratories, Inc). “The accepted target treatment goal is a cumulative
dose of 120-150mg/kg, with a typical dosing of 0.5mg/kg for the first month, followed by
1mg/kg thereafter” (Zeichner). An important part of the dosing recommendations is the
weight-based dosing regimen. Proper body weight should be recorded at initiation of
therapy. Table 1 illustrates isotretinoin dosing by body weight, based on administration
with food.
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Table 1: Isotretinoin Dosing by Body Weight (Based in Administration with Food)
Body Weight

Total mg/day

Kilograms

Pounds

0.5 mg/kg

1 mg/kg

2 mg/kg

40

88

20

40

80

59

110

25

50

100

60

132

30

60

120

70

154

35

70

140

80

176

40

80

160

90

198

45

90

180

100

220

50

100

200

In an example calculation of dosage, a female patient weighs 154 pounds. Her
dermatologist suggests the less aggressive dosage of treatment and prescribes 1
mg/kg/day. Her lab tests come in as required, and all relevant parties complete their
iPLEDGE requirements. She initiates therapy at her calculated total mg/day as follows:

Pharmacokinetics
Absorption, Distribution, Metabolism, and Elimination are the constructs of
pharmacokinetics. Absorption is influenced by the administration with a high-fat content
meal (Colburn, et al). The high lipophilicity of isotretinoin means that this drug is wellabsorbed through the membrane, but absorption is enhanced if high-fat meal is
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concurrently being absorbed (Lexicomp). Safe-use conditions evaluate more studies
behind the proper use of the drug to ensure most efficient absorption and highest success
rate for therapy. A second round of isotretinoin therapy is not unheard of, but should aim
to be avoided by reaching the proper cumulative dose in the first round of the medication.
Plasma protein, albumin, is responsible for the distribution of more that ninetynine percent of isotretinoin. Isotretinoin acts like a prodrug. It is metabolized into
different metabolites, 4-oxo-tretinoin being the most pharmacologically active
(Lexicomp). P450 enzymes responsible for the metabolism of this drug include 2C8,
2C9, 3A4, and 2B6. Isotretinoin is excreted in the urine and feces equally.
Therapeutics
Indications determined by isotretinoin manufacturers typically describe severe
nodular recalcitrant acne. It is deemed and reported that isotretinoin is most commonly
prescribed off-label for treatment of moderate acne vulgaris.
Drug Interactions
Vitamin A, tetracycline antibiotics, and micro-dosed progesterone are among
proven drug interactions with isotretinoin (Lexicomp). St. John's Wort also may work
against the efficacy of co-administered birth control methods. Corticosteroid medications
and Dilantin® (phenytoin) efficacy may also be affected while taking isotretinoin
medication (FDA medication guide).
Overview of Side Effects and Adverse Events
Table 2 outlines the side effects and adverse events associated with isotretinoin.
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Table 2: Isotretinoin Side Effects and Adverse Events
Dermatological

Dry, cracked, peeling skin
Dry lips / dry mouth
Rash, skin infection
Extremely sun-sensitive skin

Skeletal

Muscle aches, joint pain, back pain
Tenderness of the bones (decrease in bone mineral
density)
Hyperostosis and calcification of ligaments and
tendons
Potential for premature epiphyseal closure

Gastrointestinal

Possible upset stomach
Inflammatory bowel disease (regional ileitis)

Pseudotumor Cerebri
(Neurological)

Benign intracranial hypertension
(associated with concomitant use of tetracyclines)

Psychiatric

Depression
Psychosis
Suicidal ideation
Aggressive and/or violent behaviors

Other

Dry eyes and visual impairment
Corneal opacities
Decreased night vision
Dry nose that may lead to nosebleeds
Acute pancreatitis in patients with elevated serum
triglycerides
Possible elevated triglycerides (800 mg/dL)
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Impaired hearing (persistent even discontinuation of
therapy)
Black Box Warning

Debilitating birth defects
(Lexicomp, Yoder, Khoo, Layton)

Dermatological side effects listed in the table above are the most commonly
recognized side effects regarding isotretinoin. These symptoms are manageable in most
cases, but can become severe in certain patients. Dry skin is an expected symptom due to
the mechanism of action of isotretinoin. The reduction of sebaceous glands and therefore
sebum production causes a shock that the skin takes time to adjust to (Yoder). Symptoms
of this degree are typically managed by intensive-strength lotions and moisturizers. The
sun-sensitivity brought on by the drug can be combated by avoiding direct sun exposure
and applying sunscreen frequently. Patients who do not take these precautions may put
themselves at risk for damaging acne scarring or burns. The skin dryness and
dermatological side effects are typically the worst during the first two to three weeks of
treatment (Khoo).
The skeletal symptoms caused by the drug are typically not debilitating, but
should not be ignored. Joint pain, muscle aches, muscle stiffness, or muscle weakness can
be expected, but medication should be discontinued if these become extreme (Layton).
Psychiatric side effects may include depressive thoughts or even suicidal thoughts
or actions (Lexicomp). Mental health and isotretinoin treatment have brought up rising
concern of association with suicidal events. Acne treatment is an area of medicine that is
commonly associated with psychiatric struggles. Especially for Accutane patients, the
road to clear and healed skin may take the course of numerous years.
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Birth defects resulting from fetal exposure of isotretinoin include “abnormalities
of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus
and parathyroid glands” (iPLEDGE). A misshaped skull is depicted in Figure 2 below.
Babies exposed to isotretinoin also are reported to have IQ scores of less than 85.
Alongside the risk of birth defects, there is also a risk of spontaneous abortion or
premature births (iPLEDGE).

Figure 2: Misshapen Skull Associated with Fetal Exposure to Isotretinoin
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THE BLEMISHED HISTORY OF ACCUTANE®
Development and Discovery
Accutane’s basic compound is first noted in scientific literature under the
research of Dr. Werner Bollag of Roche laboratories in Switzerland during the 1960’s
(Green). The drug, originally tested for its potential efficacy against skin cancers,
provided potency against cystic acne that was worthy of further pursuit. As many
medications commonly are discovered, isotretinoin was not originally researched for the
treatment of acne. This compound was clinically studied for treatments of
dermatologically orphan diseases or other far-reaching skin conditions. Researchers
conducting these trials all noted significantly clearer skin of their patients after treatment
with isotretinoin. This remarkably potent compound, noted as a vitamin A derivative, was
suspected to be a possible danger to pregnant women. The famous thalidomide crisis of
the late 1960’s had brought teratogenic drugs and their significant hazards to the forefront
of society’s conscience. “At that time [the 1970s], in the psychological climate
engendered by the thalidomide tragedy, it would be inconceivable to develop an agent
with teratogenic properties for the treatment of such a common complaint as acne”
(Green).
This 13-cis-retanoic acid was also under development by two scientists at the
National Institutes of Health (NIH), Dr. Frank Yoder and Dr. Gary Peck. Peck and Yoder
hurriedly published news of their groundbreaking acne cure in the Lancet, a British
medical journal, on November 27, 1976 (Franz). Miscommunication between the NIH
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researchers and the Swiss Dr. Bollag led to unresolved ambiguity on the identification of
the true discoverer.
Premarketing Studies
Isotretinoin underwent rigorous clinical research studies as “Accutane” under
Hoffmann-La Roche. Animal studies concluded significant deformities and defects in
offspring, which secured Accutane’s placement as a potent and potentially teratogenic
drug. No documented studies were conducted on pregnant women, so the true extent of
the fetal abnormalities was unknown. Trials in pregnant women spark controversy and
prove to be difficult to approach properly. The premarket approval process outlined in the
table above can take numerous years. Roche submitted Accutane for FDA approval in
July 1981 (Green). The clinical research data was presented to the Dermatologic Drugs
Advisory Committee panel of specialists. This approval process approach is common
among new medications, because this smaller committee is more knowledgeable in
regards to dermatological medications. This committee suggested that Accutane be
approved for market finally in January of 1982 under contingencies that the label include
stricter pregnancy warnings. Rather than a pregnancy risk of category C, FDA ordered
Accutane to be approved under pregnancy warning category X (Green). This changed
the labelling as “studies have shown an adverse effect on the fetus and there are no
adequate and well-controlled studies in humans” to “studies in animals or humans have
demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk
based on adverse reaction data from investigational or marketing experience” (FDA).
The controversy shadowing this stipulation was that Hoffman-La Roche only
tested female participants who were given contraceptives, and the one woman who did
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become pregnant aborted (Green). The company sharply noted that they did not have
influence in this abortion against accusations of coercion. As explained, the original label
noted that no evidence proved the sure cause of birth defects in humans, while no data
had actually proven this. Nine months after application submission, Accutane® was
officially FDA-approved.
Early Years of Marketing
After the drug was first approved in 1982, obstacles quickly stacked against the
manufacturing company Hoffmann-La Roche. The 1A, top priority, fast track approval
medication surprised the company and required four additional months before the official
launch in the United States in September 1982. Over 200,000 prescriptions for Accutane
were written in only the first six months (Green).
As the popularity of the drug grew exponentially, the rising concerns of potential
toxicity rose as well. Researchers and prescribers across the country began to voice
concerns for potential birth defects, and some of these concerns were published in
esteemed journals. Even Dr. Yoder of NIH, the drug’s discoverer, “wrote a letter to
JAMA in January 1983 to ''express [his] concern and anxiety over the potential tragedy
that might arise from abuse and misuse of Accutane…the potential toxicity of this drug
has been seriously under-emphasized” (Yoder). Hoffmann-La Roche received many
notes of caution and backlash, but continued manufacturing the drug with no alterations.
The company released its first “Dear Doctor” letter of warning exactly nine months after
the medication’s release (Green). A “Dear Doctor” letter is formally known now as a
“Dear Healthcare Provider” letter, or DHCP (FDA). These letters are “correspondence ―
often in the form of a mass mailing from the manufacturer or distributor of a human drug
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or biologic or from FDA ― intended to alert physicians and other health care providers
about important new or updated information regarding a human drug or biologic” (FDA).
This letter of caution was quickly followed by the distribution of red warning stickers and
a second Dear Doctor letter. The Accutane label was adjusted to include more details
warning against the use of the medication in pregnant women (Petrocelli). The
Dermatologic Drug Advisory Committee revisited Accutane’s regulation to conclude
Roche’s need to establish strong warnings on the risk of birth defects. Other implications
followed. The JAMA published a “Medical Directors Page” to advise doctors prescribing
the drug to use proper precaution. Blood banks were also instructed to refuse donations
from Accutane patients, as the medication in their circulation could possibly interact
with a pregnant woman if she receives the transfusion.
Furthermore in 1984, a “black box” warning was assigned to the Accutane drug
with regards to the potentially debilitating birth defects. In 1998, more issues regarding
Accutane’s psychiatric side effects were brought to the attention of physicians and the
FDA. Depression, psychosis, and possible suicidal thoughts were linked to Accutane
through many different studies. The package label for Accutane was updated to include
warnings for these possible adverse events, and prescribers were notified to monitor their
patients using the medication. Starting in 2000, the prescription could not be filled until
the monthly negative pregnancy test was completed, which was helpful in part to reduce
the numbers of birth defect adverse event occurrences. 2001 marked a year of furthering
patient education and compliance. A clearer medication guide was distributed to patients
via pharmacists. Hoffmann-La Roche starts the SMART (System to Manage Accutane
Related Teratogenicity) program (Fain, et al). More and more adverse events came to the
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FDA’s attention via the Adverse Event Reporting system. After over 6,000 reports of
psychiatric events, the officials at FDA decided to work with leaders at the National
Institute of Mental Health and called for more research on retinoid’s effects on the
Central Nervous System. Hoffmann-La Roche started to include a Medication Guide in
the Accutane pack. This same year, 2002, the original patent for Accutane expired, and
FDA approved Amnesteem as the first generic version of isotretinoin. After 20 years on
the market, over 23,000 reports in the FDA Adverse Reporting System showed that the
top five events reported were alopecia (hair loss), depression, headache, dry skin, and
induced abortion purposely to end a pregnancy. The generic drug brands of isotretinoin
develop individual programs for pregnancy prevention. The FDA Joint Advisory
Committee and all of the isotretinoin producers eventually agree to link a pregnancy test
with each monthly prescription.
Increased Regulation
A huge mark in the history of Accutane and isotretinoin generics was the
development of the iPLEDGE program. Wholesalers, pharmacies, and prescribers started
to register for this program in September 2005. Patients did not register for the program
until December 30th of 2005. In March of 2006, iPLEDGE further progressed to require
the iPLEDGE pharmacies to obtain iPLEDGE system authorization before dispensing the
prescription. A designated Responsible Site Pharmacist is responsible the “point of
contact for the pharmacy and the iPLEDGE program” (iPLEDGE). Figure 3 illustrates
requirements of the iPLEDGE program.
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Figure 3: The Traceable Links of the iPLEDGE Program

The End of Accutane®
Despite increased protections for patients taking Accutane®, the severe adverse
events became too much to bear for Roche and it’s Accutane® brand. In 2009, Roche
withdrew Accutane® from its United States market, contrary to popular assumptions that
the FDA pulled Accutane® from the market. It is presumed that Roche pulled its drug as a
result of safety issues, declining sales, loss of market share, lawsuit losses, or most likely
a combination of all four (Lamb). The following announcement was made on June 26,
2009:
“Roche Holding AG, the world’s biggest maker of cancer drugs, is pulling its
Accutane acne medicine from the U.S. market after juries awarded at least $33
million in damages to users who blamed the drug for bowel disease.
Roche notified the U.S. Food and Drug Administration today that it was
withdrawing Accutane after a “reevaluation” of its product lines showed it faced
serious challenges from generic competitors, company officials said in a statement.
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“In addition, Roche has been faced with high costs from personal-injury lawsuits
that the company continues to defend vigorously,” according to the statement.
About 13 million people have taken Accutane since it went on the market in 1982.
The medication was Roche’s second-biggest selling drug before the patent expired
in 2002 and rivals started selling generic versions. Roche’s prescription market
share of the drug is now below 5 percent, the company said.” (Lamb)
Roche still markets isotretinoin as Roaccutane® in Europe. Many other generics
are still available under names such as Absorica, Amnesteem, Sotret, Myorisan, and
Zenatane, some of which were approved even after the withdrawal of branded Accutane®.
Table 3, below, summarizes these isotretinoin drugs remaining on the market.

Table 3: Drug Name and Date of Market Entry
Drug Name

Labeler

Entry Into Market

1982 – FDA Approval of Accutane
Amnesteem

Mylan Pharmaceuticals, Inc.

11/11/2002

Claravis

Teva Pharmaceuticals USA, Inc.

05/09/2003

2009 – Roche Withdrawal of Accutane
Myorisan

Akorn, Inc.

05/01/2012

Absorica

Sun Pharmaceutical Industries, Inc.

06/08/2012

Zenatane

Dr. Reddy’s Laboratories Ltd.

03/26/2013
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CURRENT REGULATION OF ISOTRETINOIN
Given the compromised safety profile of isotretinoin, the FDA has established
number safeguards for patients on the medication. Those include setting dispensing
program requirements through the FDA REMS program for isotretinoin called
“iPLEDGE”, as well as black box warnings on their package insert, which specifically
seeks to prevent fetal exposure through special dispensing requirements.
Risk Evaluation and Mitigation Strategies (REMS) and Applications to Isotretinoin
Prescription drugs on the market often come with numerous side effects ranging
from minor to life-threatening. The benefit of the medication in some cases may
outweigh the risks, so it is necessary for these drugs to pass the proper approval process.
On September 27, 2007, the Food and Drug Administration (FDA) passed an
Amendments Act that formally created a program of Risk Evaluation and Mitigation
Strategies (REMS) for the approval of these high-risk drugs (FDA). This gives FDA the
critical authority to require the manufacturer to outline and ensure that the potential
benefit of their medication outweighs the risks. This program gave officials a mechanism
to get drugs approved despite very focused safety concerns. They may have been more
inclined to reject these kinds of drug applications in the past. The US FDA website
published that there are currently 60 approved REMS (FDA). Each REMS report
includes detailed information including product name, new drug application (NDA) or
abbreviated new drug application (ANDA) application number, application holder, and
the date that the REMS was added to the database.
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REMS can be categorized as “elements to assure safe use (ETASU)”,
“communication plan”, or “medication guide”. Below is a table that includes descriptions
for the categories.
Table 4: REMS Categories
Elements to assure
safe use (ETASU)

Typically require clinicians or healthcare settings to become
certified prior to prescribing and to participate in additional
REMS activities, such as training, patient counseling, and
monitoring

Communication plan

Typically composed of letters, website, and facts sheets
describing the specific safety risks identified in the REMS

Medication guide

REMS element typically included as part of their labeling
(FDA)

REMS data files are routinely monitored and modified. Currently 49 (82%) of the
REMS include ETASU. 7 (12%) include only a communication plan. 4 (6%) include only
the medication guide. Very commonly, REMS will include more than one of these
elements (FDA).
It is up to the FDA and manufacturer to monitor if the REMS report is being
properly followed to prevent these adverse effects. This has been an ambiguous task and
proves to be difficult to assess. Adverse events can be reported in databases such as
“AERS” (Adverse Event Reporting System), but monitoring continually proves difficult.
Multiple studies, including Kevin Fain and G. Caleb Alexander’s study of “Are Food and
Drug Administration prescription drug safety plans working? A case study of
isotretinoin”, study the effectiveness of REMS (Fain, et al.). The study brings to light the
fact that “numerous studies have evaluated the impact of FDA regulatory
communications, [but] far less is known about the more recently implemented REMS
program” (Fain, et al). A case study on isotretinoin in particular showed “the median
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proportion of concomitant use of contraception with isotretinoin was 29%, which
increased an absolute 1.3% during the 24 months after iPLEDGE implementation” (Fain,
et al). This minor increase was concerning to researchers who had predicted a larger
increase. The FDA’s top priority is to ensure the safety of public health by monitoring
drugs among other food and cosmetic products.
Black Box Labeling and Applications to Isotretinoin
A Black Box warning is the FDA’s most urgent labeling system on a prescription
package (Wagner, et al.). This boxed warning serves as a way to remind patients of the
dangers of common adverse or potentially life-threatening adverse events. In a literal
sense, a black box warning is a printed warning on promotional materials or medication
guides that outline the adverse reactions you may experience during or after use
(Weyant). A Black Box prescription typically comes paired with a risk mitigation
strategy or other resources exceeding the base-level adverse event monitoring system. For
example, Accutane, and currently, isotretinoin, comes with a black box warning of
severe birth defects and warned females to not get pregnant while taking this medication.
Mitigating Fetal Exposure
The first major component of the REMS of this medication is to prevent fetal
exposure. Accutane has great potential to cause debilitating birth defects, so the
manufacturing company must take effective preventative measures. The teratogenic drug
characteristics, pharmacokinetics of pregnant women, and proper categorization of
pregnancy medications are crucial parts to this detailed risk evaluation and mitigation
strategy.
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As previously stated, Accutane® and isotretinoin generics are highly teratogenic
compounds. A teratogen is broadly defined as a drug that has the potential to cause birth
defects. Teratogenic drugs may cross into the developing fetus’s blood supply via the
mother's blood. The the transfer of blood from the mother to the placenta is illustrated.
This transfer of blood carries all of the mother’s important nutrients, gases, antibodies,
and other molecules. Unfortunately, the mother’s metabolism and ability to excrete
harmful substances is much further developed than the unborn babies. This explains why
pregnant women must closely monitor their intake of toxic substances, medications, and
potentially harmful metabolites.
Drugs cross into the fetal blood supply via passive diffusion, facilitated diffusion,
and active transport (Gunatilake). This indicates that mainly freely unbound drugs cross
the placenta. As isotretinoin is a fat-soluble drug, the active metabolites easily cross over
into the placenta. This harmfully affects development in numerous organ systems,
especially the central nervous system, cardiovascular system, and endocrine system. In
some cases, isotretinoin’s teratogenicity and high potency may cause spontaneous
abortions.
Broadly, birth defects may range in severity due to the variety of dose, gestational
age at the time of exposure, and type of drug (Gunatilake). Higher doses of certain
teratogenic medications may be discontinued if possible or lowered dose prescribed to
minimize fetal toxicity. As a pregnant woman’s blood plasma volume increases by thirty
to fifty percent (Sachdeva, et al) and many other pharmacokinetic factors are altered,
distribution of drug in maternal blood stream may vary widely. There is an increase in
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body fat during pregnancy as well. This indicates that fat soluble drugs will be distributed
to a greater volume which may have a more widespread potency (Gunatilake).
Furthermore, the gestational age at the time of drug exposure is also critical to the
risk of birth defects. The fetal development is culminated in forty weeks. This time period
can also be categorized into three trimesters. Women who are planning to become
pregnant are typically advised to withdraw their unnecessary medication usage three to
six months before conception. Drugs or harmful substances can remain within the
mother’s blood system for various ranges of time, but it is safer to ensure that drugs will
not be transferred to the baby after conception. The early days and weeks following
conception are crucial periods of development. Within the first two weeks after
conception, the drugs cause an “all-or-nothing effect” (Gunatilake). Some women may
not know that they are pregnant during this time and may not have discontinued harmful
medications. The fertilized egg may not implant properly, spontaneous abortion may
occur in early pregnancy, or the drug may have no effect. In three to eight weeks after
fertilization the fetal organs are developing in a stage called organogenesis. During this
stage, the baby is most susceptible to birth defects. In the second and third trimesters,
fetal development is majorly growth and maturation. Since primary organ development is
complete, drugs are unlikely to cause obvious birth defects.
The type of drug plays a vital part in the potential for birth defects. Examples of
commonly used drugs that are teratogenic include Angiotensin Converting Enzyme
(ACE) inhibitors, thalidomide, warfarin, male hormones, some anticonvulsant
medications, high doses of Vitamin A, and numerous others (Sachdeva, et al.). Pregnancy
poses a unique physiological state and pharmacology of all medications. The Food and
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Drug Administration recognizes that total avoidance of all drugs or medications may be
unfeasible for many patients. Certain women may require medication for chronic disease
management such as asthma, epilepsy, hypertension, or psychiatric conditions (Sachdeva,
et al). In addition to certain chronic conditions, some women develop acute conditions
that require pharmacological intervention during gestation. Gestational diabetes,
exacerbated migraine symptoms, high blood pressure related to pregnancy, anemia, or
various infections can occur during pregnancy and must be treated (Sachdeva, et al).
The FDA has created a categorization for various drugs used in pregnancy in
1979. As a result of the thalidomide crisis in the late 1960’s, many pregnant women were
delivering babies with congenital abnormalities including phocomelia, a condition that
involves the malformation of the arms and legs. This refined system developed rankings
for teratogenic risk. The categories A, B, C, D, and X outline the level of risk associated
with taking the drug while pregnant and are further defined in the table below.

23

Table 5: Pregnancy Categories and Description
Category A

Adequate and well-controlled studies have failed to demonstrate a risk
to the fetus in the first trimester of pregnancy (and there is no evidence
of risk in later trimesters)

Category B

Animal reproduction studies have failed to demonstrate a risk to the
fetus and there are no adequate and well-controlled studies in pregnant
women

Category C

Animal reproduction studies have shown an adverse effect on the fetus
and there are no adequate and well-controlled studies in humans, but
potential benefits may warrant use of the drug in pregnant women
despite the potential risks

Category D

There is positive evidence of human fetal risk based on adverse
reaction data from investigational or marketing experience or studies
in humans, but potential benefits may warrant use of the drug in
pregnant women despite potential risks

Category X

Studies in animals or humans have demonstrated fetal abnormalities
and/or there is positive evidence of human fetal risk based on adverse
reaction data from investigational or marketing experience, and the
risks involved in use of the drug in pregnant women clearly outweigh
potential benefits.
(US Department of Health and Human Services)

The table below lists examples of commonly prescribed medications within each
category.
Table 6: Pregnancy Category Examples
Category A

Vitamins B, C, D, E, folic acid

Category B

acetaminophen, amoxicillin

Category C

Antimalarials, antifungals, gentamicin, aspirin

Category D

Tetracyclines, streptomycin, ACE inhibitors

Category X

Androgens, estrogens, bronchodilators, thalidomide, oral
contraceptives, statins
(FDA)
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Specifically pertaining to isotretinoin, pregnancy precautions have been very
closely considered and monitored. Isotretinoin is given both a Black Box pregnancy
warning and Category X pregnancy medication rating. Manufacturers are required per
their REMS agreement to ensure that patients are properly informed and measures are
taken to prevent fetal exposure.
Dispensing Requirements
Accutane, as a high-risk drug, has numerous stringent dispensing requirements
in place in order to increase proper safety of the medication. A patient cannot simply get
prescribed Isotretinoin and go to receive their prescription. The “iPLEDGE” program was
developed as a strategy to further prevent pregnancy while completing isotretinoin
therapy. Table 7 outlines monthly required iPLEDGE interactions, and Table 8 outlines
laboratory requirements
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Table 7: Monthly Required iPLEDGE Interactions

Female patients of
childbearing potential

Male patients, and female
patients not of childbearing
potential

Confirms patient counseling

x

x

Enters the 2 contraception
methods chosen by the
patient

x

Enters pregnancy test results

x

Prescriber

Patient
Answers educational
questions before every
prescription

x

Enters 2 forms of
contraception

x

Pharmacist
Contacts system to get an
authorization

x

x
(iPLEDGE)
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Table 8: Laboratory Requirements for Isotretinoin Prescription Monitoring
Pregnancy tests

TWO negative urine or serum pregnancy tests
First “screening” test: obtained by prescriber
Second “confirmation” test: CLIA certified laboratory at
least 19 days after first test
• During first 5 days of menstrual period preceding
start of therapy

Lipids

Monitor for hypertriglyceridemia

Liver function tests

Monitor for elevation of liver enzymes

Glucose

Monitor for problems controlling blood glucose

Creatinine Phosphokinase Monitor for elevated levels of enzyme suggesting
(CPK)
musculoskeletal problems
(iPLEDGE)
iPLEDGE
All patients must comply with iPLEDGE stipulations in order to receive their
prescription. The following conditions must be met:
•

Must be registered with iPLEDGE program by the prescriber

•

Must understand that severe birth defects can occur with use of isotretinoin by
female patients

•

Must be reliable in understanding and carrying out instructions

•

Must sign a patient information/ informed consent

•

Must fill and pick up prescription within 7 days of specimen collection
(female/childbearing potential)

•

Must fill and pick up prescription within 30 days of office visit (male
patients/non-childbearing potential)
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•

Must not donate blood while on isotretinoin and for one month after treatment
cessation

•

Must not share isotretinoin with anyone (FDA medication guide)
As discussed, strict prescribing rules require two forms of birth control and

monthly blood monitoring including pregnancy tests. Commitment to abstinence can
allow patients to avoid two forms of birth control Table 9 below outlines the primary and
secondary forms of contraception outlined on the iPLEDGE website.

Table 9: Acceptable Primary and Secondary Forms of Birth Control
Primary forms of Birth Control
Implantable Hormones

Hormonal IUD

Partners Vasectomy

Tubal Sterilization

Non-Hormonal IUD

Hormonal Injection

Hormonal transdermal patch

Hormonal Vaginal Ring

Hormonal Combination Oral
Contraceptives

Secondary Forms of Birth Control
Male Latex Condom

Cervical Cap

Diaphragm

Cervical Sponge

Safe Use Conditions
Isotretinoin is advised to be administered with meals. Numerous case studies have
proven that the oral absorption of isotretinoin is beneficially maximized when given with
a high-fat meal. A crossover study of 74 healthy adult subjects receiving an 80 mg oral
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dose compared the AUC of fasted and fed conditions. Both peak plasma concentration
and area under the curve of the active ingredient more than doubled following a high-fat
meal. A “high fat” is defined by the FDA “as [fat making up] 50 percent of total caloric
intake of the meal” (Zeichner). High-fat ingredient suggestions include fatty fish like
salmon, avocados, extra virgin olive oils, and cheeses. Many prescribers are not properly
educating their patients on the proper safe-use techniques. This may lead to unsuccessful
treatment and a need for a second round of isotretinoin therapy. The generic Absorica is
the first to provide the same efficacy with or without a meal.
An open randomized crossover design study of twenty males also concluded that
“coadministration of isotretinoin with food may be the best method of administration”
(Wayne, et al). Isotretinoin blood concentrations determined by an HPLC method
supported prior publications suggesting the increased bioavailability with food within a
one-hour window of oral administration (Wayne, et al.). The relative bioavailability
(AUC) of these subjects was found to be about two times higher when medication was
“taken one hour before, concomitantly with, or one hour after a meal” (Colburn, et al.).
The responsibility of safe-use suggestions falls in the hands of the prescribing
practitioners and dispensing pharmacists. In order to dispense isotretinoin, pharmacies
must be registered and certified through the iPLEDGE program as active. Similarly,
dermatologists or other prescribing physicians must complete a training program through
iPLEDGE in order to be registered to prescribe the drug.
Patient Adherence
As outlined in the iPLEDGE regulations, the prescriber, pharmacist, and patient
must all complete the required steps within the specified time frame. Strenuous
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circumstances or undue hardship may lead to patient noncompliance. Failure to fill
prescription on time may lead to an inefficient dosing schedule and decreased efficacy of
the isotretinoin course. Under-dosing and patient noncompliance are common causes of
relapse or re-treatment. Patient factors for unsuccessful therapy cannot be controlled, but
prescriber-caused insufficiency should be minimized or eliminated.
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CONCLUSION
Accutane has a rich history of litigation and controversy. The conflict between
brand-name discoveries and generic liabilities is an ongoing discussion that continues to
prove difficult to reach a consensus. The FDA, the pharmaceutical industry, and the
healthcare industry, in general, have responded to high risk drugs (like Accutane)
through many different pursuits including the establishment of lengthy Risk Evaluation
and Mitigation Strategies. The REMS of isotretinoin aims to (1) to prevent fetal exposure
and (2) to inform prescribers, pharmacists, and patients about isotretinoin’s serious risks
and safe-use conditions (FDA). These strategy’s success and true significance is difficult
to measure, and I intend to pursue further research on the data behind the success of the
iPLEDGE program.
As a current discussion and implication of the COVID-19 public health
emergency, FDA released a statement stating that it does not plan to punish sponsors that
fail to adhere to the REMS requirements for certain laboratory testing. This is an
unprecedented alteration to the REMS requirements as this is a difficult time for our
general population. For patients currently taking isotretinoin, this means that laboratory
monitoring requirements will be waived. In addition, pregnancy tests will be completed
at-home and communicated to the prescribers via telehealth.
Throughout the process of this thesis, I learned about isotretinoin in great detail. I
am interested in pursuing research behind other REMS programs and their success rates.
In my opinion, the iPledge program may not be proving sufficient in protection and
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prevention of the critical adverse events that isotretinoin can cause. Women are still
becoming pregnant despite the strict warnings and requirements, and that is problematic!
Moreover, I started this project with intentions to pursue more of the lawsuits and
litigation side of Accutane, but learned through my early research that I was much more
interested in the regulatory side and specific goals of the REMS. The regulatory
development of this high-risk drug is fascinating as well as its attempt to combat adverse
events. The two goals of isotretinoin REMS were interesting to explore in further detail.
In particular, I am very interested in the pharmacology of birth defects and the pregnancy
categories. Isotretinoin is ranked as category X along with other medications, and I am
interested in learning more about the other category X medications and what exactly their
mechanisms of actions are. This broad category of isotretinoin as a whole has led me to
many new interests in various area of study.
Accutane’s unsurpassed efficacy is paired with serious risk of adverse events
and birth defects, which poses ethical questions regarding its safety and necessity. Its
regulatory history established precedent in Food and Drug Administration Risk
Evaluation and Mitigation Strategies and brought awareness to the sharp dangers of
teratogenic drug use. Some question the risk-benefit evaluation of such a toxic drug for
acne. Accutane and isotretinoin generic drugs have changed the lives of over two
million patients (AOCD). These drugs will continue to be prescribed and dispensed to
patients daily, so it is of utmost importance to ensure that these dangerous medications
are being monitored properly while preventing adverse events.
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